For
the quarter ending March 2024, standalone Net sales (including other operating income) of RPG Life Sciences has increased 7.17% to Rs 126.99 crore compared to quarter ended March 2023. Operating profit margin has jumped from 13.43% to 16.32%, leading to 30.23% rise in operating profit to Rs 20.72 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 18.43% to 21.81%. Purchase of finished goods cost fell from 16.65% to 11.61%. Employee cost decreased from 27.75% to 24.96%. Other expenses rose from 24.10% to 25.49%. Other income fell 10.33% to Rs 1.65 crore. PBIDT rose 26.03% to Rs 22.37 crore. Provision for interest up 180% to Rs 0.14 crore. Loan funds remained nil. Inventories rose to Rs 101.00 crore as of 31 March 2024 from Rs 95.05 crore as of 31 March 2023. Sundry debtors were higher at Rs 49.13 crore as of 31 March 2024 compared to Rs 37.43 crore as of 31 March 2023. Cash and bank balance declined from Rs 57.04 crore as of 31 March 2023 to Rs 36.47 crore as of 31 March 2024. Investments rose to Rs 91.16 crore as of 31 March 2024 from Rs 58.43 crore as of 31 March 2023 .
PBDT rose 25.59% to Rs 22.23 crore. Provision for depreciation rose 15.42% to Rs 4.49 crore. Fixed assets increased to Rs 181.81 crore as of 31 March 2024 from Rs 116.30 crore as of 31 March 2023. Intangible assets declined from Rs 33.40 crore to Rs 28.03 crore.
Profit before tax grew 28.46% to Rs 17.74 crore. Provision for tax was expense of Rs 4.5 crore, compared to Rs 3.46 crore. Effective tax rate was 25.37% compared to 25.05%.
Profit after tax rose 27.92% to Rs 13.24 crore.
Equity capital stood at Rs 13.23 crore as of 31 March 2024 to Rs 13.23 crore as of 31 March 2023. Per share face Value remained same at Rs 8.00.
Promoters’ stake was 72.81% as of 31 March 2024 ,compared to 72.81% as of 31 March 2023 .
Full year results analysis
Net sales (including other operating income) of RPG Life Sciences has increased 13.50% to Rs 582.05 crore. Operating profit margin has jumped from 20.03% to 22.02%, leading to 24.79% rise in operating profit to Rs 128.15 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 16.56% to 20.83%. Purchase of finished goods cost fell from 17.70% to 10.56%. Employee cost increased from 22.51% to 22.81%. Other expenses rose from 23.49% to 23.69%. Other income up 50.21% to Rs 7.21 crore. PBIDT rose 25.93% to Rs 135.36 crore. Provision for interest up 45.16% to Rs 0.45 crore. Loan funds remained nil. Inventories rose to Rs 101.00 crore as of 31 March 2024 from Rs 95.05 crore as of 31 March 2023. Sundry debtors were higher at Rs 49.13 crore as of 31 March 2024 compared to Rs 37.43 crore as of 31 March 2023. Cash and bank balance declined from Rs 57.04 crore as of 31 March 2023 to Rs 36.47 crore as of 31 March 2024. Investments rose to Rs 91.16 crore as of 31 March 2024 from Rs 58.43 crore as of 31 March 2023 .
PBDT rose 25.87% to Rs 134.91 crore. Provision for depreciation rose 10.13% to Rs 17.07 crore. Fixed assets increased to Rs 181.81 crore as of 31 March 2024 from Rs 116.30 crore as of 31 March 2023. Intangible assets declined from Rs 33.40 crore to Rs 28.03 crore.
Profit before tax grew 28.53% to Rs 117.84 crore. Provision for tax was expense of Rs 30.18 crore, compared to Rs 24.04 crore. Effective tax rate was 25.61% compared to 26.22%.
Profit after tax rose 29.60% to Rs 87.66 crore.
Equity capital stood at Rs 13.23 crore as of 31 March 2024 to Rs 13.23 crore as of 31 March 2023. Per share face Value remained same at Rs 8.00.
Promoters’ stake was 72.81% as of 31 March 2024 ,compared to 72.81% as of 31 March 2023 .
Cash flow from operating activities increased to Rs 94.36 crore for year ended March 2024 from Rs 90.82 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 69.23 crore, compared to Rs 32.73 crore during the year ended March 2023.
Business highlights
The
board Recommended equity dividend of Rs 16 per share of Rs 8 each (200 %) for
the financial year ended March 31, 2024.